The Annual Meeting program is subject to change. Speakers are added as confirmations are received.
Please  note that Quality College workshops require separate registration.

Please review the Safety Rules and Guidelines.
Back To Schedule
Wednesday, April 11 • 3:30pm - 5:00pm
Session Z - GLP Track

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Feedback form is now closed.
Z-1  How the Poison Squad contributed to the 1906 Pure Food and Drug Act 

Dr. Harvey Wiley’s concern for pure food led him to question the safety of chemical preservatives in the public food supply.  At that time, it was common to preserve meats with saltpeter, ketchup with benzoic acid, and milk with formaldehyde, just to name a few.  Starting in 1902, he formed the Poison Squad, to test the effects of some of the most commonly used food additives on human volunteers.  Young men volunteered for these trials, pledging one year of service to receive three square meals a day of intentionally poisoned food.  The information generated by these ‘human lab rats’ led, in part, to the promulgation of the 1906 law.


Level of Content:

Z-2 GLP Test, Control and Reference Substance Preparation and Characterization: The Roles of the Study Director, Test Facility Management and the Quality Assurance Unit

Vincella Erickson, Carol Lee and Margaret Coyle-Rees, Ph.D, RQAP-GLP
Under the Final Rule of the Federal Insecticide, Fungicide and Rodenticide Act, the EPA clearly states that characterization of test, control and reference substances intended to be used in studies meant to support research and marketing permits under 40 CFR Part 160 is necessary to ensure the integrity of studies. Characterization testing is typically conducted at the production or synthesis phase and must therefore be available on or before a study is initiated. Requirements for the production or synthesis are not addressed in the regulation in the same manner as is the characterization; however, the accuracy and retention of such records to support the preparation of test, control and reference substances are critical to support the reconstruction of the study. This presentation provides a framework for good documentation practices on test, control and reference substance preparation, and the importance of such documentation for the US EPA GLP requirement of characterization. Further, the impact of the OECD GLP Draft Advisory Document 19 on the Management, Characterization and Use of Test Items will be discussed, as well as the roles and responsibilities of the Study Director, Test Facility Management and the Quality Assurance Unit.

Good Laboratory Practices - EPA

Level of Content:

Z-3  Quality Systems for Small Companies: The Struggle is Real ...  and so is the Cost of Nonquality

I can't take it anymore. Well, I can but I don't want to. I'm seeing a disturbing trend in my travels around the country as a quality assurance (QA)/systems consultant. It has to do with small pharma and biotech companies as well as small vendor companies that provide services to them.  It also involves QA professionals. I'm seeing small companies that: 1) have no true QA presence 2) are giving QA responsibilities to staff members who have little to no QA experience, and/or 3) have QA staff who don't have the right type of QA experience. There are several reasons for this trend including but not limited to: 1) Small companies don't often have the budget to hire a QA Director with big pharma experience or over ten years of experience that counts and 2) They love to promote from within. This presentation will explore this trend and provide specific tips and strategies small companies can use to build the robust quality system needed to successfully operate in the pharmaceutical and biotech industry.  Your product may be stellar! Your company's technical expertise may be outstanding! You may deliver fantastic clinical results! However, if your quality system is weak; if it causes issues for a sponsor company; if it introduces gaps and concerns for regulators; if clinical trials can't be reconstructed; if data quality is questionable; if patient safety suffers .... the ultimate kick in the gut will happen in your financials. That's called the cost of nonquality ... and it's real.


Level of Content:


Eva Haszcz

Gloabal Quality Programs Manager, FMC Corporation, Agricultural Solutions
Ms Haszcz has 17 years of experience working in GLP and GMP regulated environments. Since 2009 she is the Global Quality Programs Manager within the Regulatory Department at FMC Corporation. Through her work in a global regulatory setting she has gained an extensive understanding... Read More →

avatar for Vincella Erickson

Vincella Erickson

Valent USA Corporation
Ms. Erickson facilitates all Valent Technical Center GLP Standards and QA activities including in-life, raw data and final report audits; assists in the establishing of policies and procedures to ensure compliance with domestic and international GLP standards for Valent QA operations... Read More →
avatar for Barbara Munch

Barbara Munch

Barb Munch, BS, is Director, R&D Pharma GLP Risk Coordinator in global toxicology, within GlaxoSmithKline (PA, UK). This group conducts GLP in-vivo and in-vitro toxicology studies for pharmaceutical test articles. Her 39-year career has been in the nonclinical regulatory environment... Read More →
avatar for Penelope Przekop

Penelope Przekop

CEO/Principal Consultant, PDC Quality Consulting
Penelope Przekop is an outcome-driven Senior Executive and Thought Leader with more than 25 years of success across the biotech, pharmaceutical, healthcare, teaching hospital, clinical trials, manufacturing, and design industries. Her broad areas of expertise include quality assurance... Read More →

Wednesday April 11, 2018 3:30pm - 5:00pm PDT
Platinum 5&6